We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-1.86%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$14.7B
AUM Growth
-$908M
Cap. Flow
-$379M
Cap. Flow %
-2.57%
Top 10 Hldgs %
84.38%
Holding
107
New
11
Increased
15
Reduced
16
Closed
4

Top Buys

Rank Stock Value
1
BCEL
Atreca, Inc. Class A Common Stock
BCEL
+$63.8M
2
ADPT icon
Adaptive Biotechnologies
ADPT
+$51.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$26M
4
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$22.4M
5
HRTX icon
Heron Therapeutics
HRTX
+$20M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$184M
2
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$97.2M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$69.5M
4
GHDX
Genomic Health, Inc.
GHDX
+$55.6M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$38.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.62%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRS
51
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$9.03M 0.06%
97,484
+40,000
+70% +$2.79M
ALKS icon
52
Alkermes
ALKS
$8.11B
$9.02M 0.06%
400,000
+333,000
+497% +$9.13M
DERM
53
DELISTED
Dermira, Inc.
DERM
$8.67M 0.06%
906,943
– –
ALBO
54
DELISTED
Albireo Pharma Inc
ALBO
$8.06M 0.05%
250,000
– –
APLS
55
DELISTED
Apellis Pharmaceuticals
APLS
$7.95M 0.05%
313,725
– –
MIST icon
56
Milestone Pharmaceuticals
MIST
$131M
$7.24M 0.05%
+266,667
New +$5.5M
ANAB icon
57
AnaptysBio
ANAB
$1.71B
$6.38M 0.04%
113,086
– –
ABEO icon
58
Abeona Therapeutics
ABEO
$348M
$6.16M 0.04%
51,529
– –
HOOK
59
DELISTED
HOOKIPA Pharma
HOOK
$6.01M 0.04%
+89,286
New +$9.47M
ORTX
60
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$5.68M 0.04%
40,570
+28,070
+225% +$4.93M
HALO icon
61
Halozyme
HALO
$12.3B
$5.15M 0.04%
299,969
– –
BLUE
62
DELISTED
bluebird bio
BLUE
$5.09M 0.03%
3,088
– –
BLCM
63
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$4.55M 0.03%
267,782
– –
YARW
64
Yarrow Bioscience
YARW
$97.2M
$4.19M 0.03%
194
– –
GTHX
65
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$3.9M 0.03%
127,236
– –
NGM
66
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$3.66M 0.02%
+250,000
New +$3.66M
VKTX icon
67
Viking Therapeutics
VKTX
$3.95B
$3.53M 0.02%
425,000
– –
XLRN
68
DELISTED
Acceleron Pharma
XLRN
$3.45M 0.02%
83,900
– –
CRNX icon
69
Crinetics Pharmaceuticals
CRNX
$8.99B
$3.33M 0.02%
132,985
+1,735
+1% +$43K
LKFT
70
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$3.23M 0.02%
25,072
– –
ACHN
71
DELISTED
Achillion Pharmaceuticals
ACHN
$2.94M 0.02%
1,095,359
– –
ARAV
72
DELISTED
Aravive, Inc. Common Stock
ARAV
$2.91M 0.02%
484,947
+54,062
+13% +$337K
XBIT icon
73
XBiotech
XBIT
$69.5M
$2.88M 0.02%
+380,442
New +$3.31M
HARP
74
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$2.79M 0.02%
21,429
– –
FTSV
75
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$2.65M 0.02%
250,000
– –
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2019 Portfolio in Review

As of Q2 2019, Julian Baker held 107 positions worth $14.7B, down 5.8% from $15.6B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Julian Baker's Q2 2019 filing shows 11 new, 15 increased, 16 reduced and 4 closed positions. Its largest new stake was Atreca, Inc. Class A Common Stock: 3,532,760 shares worth $66.6M. The largest sale was Incyte, an estimated $184M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q2 2019 buy was Atreca, Inc. Class A Common Stock: 3,532,760 shares worth $66.6M.
  • Julian Baker added most to Neurocrine Biosciences in Q2 2019, an estimated $26M increase.
  • Julian Baker's biggest Q2 2019 reduction was Incyte, cutting an estimated $184M.
  • Julian Baker fully exited Clementia Pharmaceuticals Inc. in Q2 2019, selling an estimated $97.2M.
  • Julian Baker's ten largest holdings make up 84% of its $14.7B portfolio in Q2 2019.
  • Julian Baker opened 11 new positions and closed 4 in Q2 2019.
  • Julian Baker's portfolio value fell 5.8% quarter-over-quarter to $14.7B.

Based on Baker Bros. Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.